HK1215934A1 - 肽治疗剂及其使用方法 - Google Patents

肽治疗剂及其使用方法 Download PDF

Info

Publication number
HK1215934A1
HK1215934A1 HK16103877.4A HK16103877A HK1215934A1 HK 1215934 A1 HK1215934 A1 HK 1215934A1 HK 16103877 A HK16103877 A HK 16103877A HK 1215934 A1 HK1215934 A1 HK 1215934A1
Authority
HK
Hong Kong
Prior art keywords
methods
same
peptide therapeutics
glp
dmt
Prior art date
Application number
HK16103877.4A
Other languages
English (en)
Chinese (zh)
Inventor
D Travis Wilson
Original Assignee
Stealth Peptides International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International, Inc. filed Critical Stealth Peptides International, Inc.
Publication of HK1215934A1 publication Critical patent/HK1215934A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
HK16103877.4A 2012-12-06 2013-04-11 肽治疗剂及其使用方法 HK1215934A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734293P 2012-12-06 2012-12-06
US201261734293P 2012-12-06
PCT/US2013/036214 WO2014088631A1 (en) 2012-12-06 2013-04-11 Peptide therapeutics and methods for using same

Publications (1)

Publication Number Publication Date
HK1215934A1 true HK1215934A1 (zh) 2016-09-30

Family

ID=49549068

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103877.4A HK1215934A1 (zh) 2012-12-06 2013-04-11 肽治疗剂及其使用方法

Country Status (7)

Country Link
US (3) US20130303436A1 (cg-RX-API-DMAC10.html)
EP (3) EP3287172A1 (cg-RX-API-DMAC10.html)
JP (3) JP2016506391A (cg-RX-API-DMAC10.html)
CN (1) CN104994912A (cg-RX-API-DMAC10.html)
CA (1) CA2894182A1 (cg-RX-API-DMAC10.html)
HK (1) HK1215934A1 (cg-RX-API-DMAC10.html)
WO (1) WO2014088631A1 (cg-RX-API-DMAC10.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4397314B1 (en) * 2012-10-22 2025-12-03 Stealth BioTherapeutics Inc. Treatment of left ventricular remodeling
WO2015057315A1 (en) * 2013-09-04 2015-04-23 Kelly Joseph Michael Lawless Methods and systems for the detection of disease
WO2015089316A1 (en) * 2013-12-12 2015-06-18 Cornell University Methods for preventing and treating oral cancers
CA2933405A1 (en) * 2013-12-13 2015-06-18 Medimmune Limited Protease-resistant peptides
EP3082838A4 (en) * 2013-12-16 2017-07-26 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
CN106132984B (zh) * 2013-12-27 2020-12-08 康德生物医疗技术公司 药学相关的芳香族阳离子肽
CN106459169A (zh) * 2014-03-03 2017-02-22 康德生物医疗技术公司 药学上相关的芳香族阳离子肽
WO2015183970A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including flavonoid and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
WO2015183988A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including therapeutic small molecules and uses thereof
US10576124B2 (en) * 2014-05-28 2020-03-03 Stealth Biotherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
WO2015183963A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2015183985A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including naphthoquinones and uses thereof
US10627392B2 (en) 2014-06-17 2020-04-21 Stealth Biotherapeutics Corp Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
US10744178B2 (en) * 2014-08-21 2020-08-18 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of disease
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US12472157B2 (en) 2014-11-07 2025-11-18 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa with n-acetylcysteine amide
US12667548B2 (en) 2014-11-07 2026-06-30 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide
WO2016077422A1 (en) * 2014-11-11 2016-05-19 The Johns Hopkins University Biomarkers useful in the treatment of subjects having retinits pigmentosa
US11268964B2 (en) * 2014-11-11 2022-03-08 The Johns Hopkins University Biomarkers useful in the treatment of subjects having diseases of the eye
JP6854771B2 (ja) * 2015-03-06 2021-04-07 ステルス バイオセラピューティックス コープ 薬学的に適切なペプチドを調製するための方法
WO2016190852A1 (en) * 2015-05-26 2016-12-01 Stealth Peptides International, Inc. Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof
WO2016195663A1 (en) * 2015-06-02 2016-12-08 Stealth Peptides International, Inc. Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
AU2016379403B2 (en) * 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
ES3057779T3 (en) 2016-01-15 2026-03-04 Childrens Medical Ct Corp Therapeutic use of mitochondria and combined mitochondrial agents
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
CN105987839B (zh) * 2016-06-03 2018-09-28 浙江世纪康大医疗科技股份有限公司 一种edta-柠檬酸抗原修复液
CN105987840B (zh) * 2016-06-03 2018-09-28 浙江世纪康大医疗科技股份有限公司 一种柠檬酸抗原修复液
WO2017210668A1 (en) * 2016-06-03 2017-12-07 Jt Pharmaceuticals, Inc. Sustained release compositions of kappa-opioid receptor agonist
CN107042067B (zh) * 2017-05-24 2019-11-08 天津大学 聚硅氧烷-金属有机框架材料杂化渗透蒸发复合膜及其制备与应用
CA3067890A1 (en) * 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
EP3443980A1 (en) * 2017-08-15 2019-02-20 Ciliocure Limited Compound for the treatment of patients with leptin-resistant obesity, bardet-biedl syndrome and other ciliopathies
CA3079196C (en) 2017-09-20 2021-05-18 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide and derivatives thereof
US12662449B2 (en) 2017-09-20 2026-06-23 Nacuity Pharmaceuticals, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US11091433B2 (en) 2017-09-20 2021-08-17 Nacuity Pharmaceutials, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US11548851B2 (en) 2017-09-20 2023-01-10 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide and derivatives thereof
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
WO2019201333A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 Glp-1衍生物及其治疗用途
AU2020206139A1 (en) 2019-01-11 2021-07-29 Nacuity Pharmaceuticals, Inc. Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with N-acetylicysteine amide (NACA) or 2R,2R')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (diNACA)
JP7631200B2 (ja) 2019-01-11 2025-02-18 ナキュイティ ファーマシューティカルズ， インク． 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）
JP7638265B2 (ja) * 2019-07-24 2025-03-03 ステルス バイオセラピューティクス インコーポレイテッド 神経変性疾患の治療におけるペプチド模倣化合物（ｒ）－２－アミノ－ｎ－（（ｓ）－ｌ－（（（ｓ）－５－アミノ－ｌ－（３－ベンジル－１，２，４－オキサジアゾール－５－イル）ペンチル）アミノ）－３－（４－ヒドロキシ－２，６－ジメチルフェニル）－ｉ－オキソプロパン－２－イル）－５－グアニジノペンタンアミド
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
KR102503914B1 (ko) * 2020-09-01 2023-02-24 인제대학교 산학협력단 황반변성 세포모델의 제조방법
US20230381281A1 (en) * 2020-10-16 2023-11-30 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating lupus-related diseases
KR20230125802A (ko) * 2020-12-11 2023-08-29 아이피2아이피오 이노베이션스 리미티드 신규 화합물
CN112618966B (zh) * 2020-12-18 2023-07-28 北京宏强富瑞技术有限公司 一种多波长激光针刺仪
CN113421648B (zh) * 2021-06-21 2024-04-23 中国科学院北京基因组研究所(国家生物信息中心) 一种用于预测射血分数保留型心衰风险的模型
CN113588375B (zh) * 2021-08-20 2023-09-29 中科光华(西安)智能生物科技有限公司 一种高稳定性骨及骨肿瘤组织微阵列芯片及其制备方法
CN116262134A (zh) * 2021-12-15 2023-06-16 联邦生物科技(珠海横琴)有限公司 一种稳定的多剂量给药的glp-1受体激动剂的制剂及其制备方法和应用
CN114480449A (zh) * 2022-03-17 2022-05-13 天津医科大学总医院 布拉氏酵母菌CNCMI-745衍生蛋白Trx2及其在制备防治腹泻药物中的应用
CN114949184A (zh) * 2022-05-13 2022-08-30 华中科技大学同济医学院附属同济医院 Glp-1代谢物在制备减轻急性肾损伤药物中的用途
US20260165992A1 (en) * 2024-12-13 2026-06-18 Neuronasal, Inc. Treatment of central nervous system diseases with n-acetylcysteine and glucagon-like peptide-1 receptor agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
PT1263464E (pt) 2000-03-09 2012-12-17 Genzyme Corp Utilização de anticorpos anti-tgf-beta antagonistas para tratar ou para prevenir a perda da função renal
CA2447008A1 (en) 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
EP1411968B1 (en) * 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
EP1701731A4 (en) 2003-12-12 2009-08-05 Einstein Coll Med GLP-1 (9-36) METHOD AND COMPOSITIONS
US20090202497A1 (en) * 2005-08-23 2009-08-13 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
US20100286029A1 (en) * 2007-09-11 2010-11-11 Dorian Bevec Use of a peptide as a therapeutic agent
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
DK2344519T3 (en) 2008-11-07 2017-01-23 Massachusetts Gen Hospital C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1)
CA2770688C (en) * 2009-08-12 2018-06-05 Cornell University Methods for preventing or treating metabolic syndrome
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
CN102614514B (zh) * 2011-01-26 2014-12-10 王永祥 Glp-1受体激动剂用于治疗疼痛

Also Published As

Publication number Publication date
EP2928562A1 (en) 2015-10-14
CN104994912A (zh) 2015-10-21
WO2014088631A1 (en) 2014-06-12
EP2928562A4 (en) 2016-06-22
US20160101158A1 (en) 2016-04-14
JP2016506391A (ja) 2016-03-03
CA2894182A1 (en) 2014-06-12
EP3459598A1 (en) 2019-03-27
US20180344814A1 (en) 2018-12-06
JP2019069942A (ja) 2019-05-09
US20130303436A1 (en) 2013-11-14
EP3287172A1 (en) 2018-02-28
JP2018021033A (ja) 2018-02-08

Similar Documents

Publication Publication Date Title
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
HK1198869A1 (en) Combination treatments for hepatitis c
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
WO2012103038A9 (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
HK1249011A1 (zh) 包括线粒体分裂抑制肽的治疗组合物、其变体及这些的使用方法
WO2012054500A3 (en) Compositions for drug administration
WO2009094172A3 (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
MX348823B (es) Formulaciones estables de linaclotida.
WO2013090278A3 (en) Intranasal dexmedetomidine compositions and methods of use thereof
WO2012009171A3 (en) Compositions and methods of treatment of corneal endothelium disorders
HK1210953A1 (en) Methods for treatment of atherosclerosis
PH12013500784A1 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
MX2021005317A (es) Composiciones y métodos para absorción transmucosa.
MX2009010689A (es) Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales.
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
WO2012064302A3 (en) Improved montelukast formulations
PH12014500381A1 (en) Therapeutic methods
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2015183984A3 (en) Therapeutic compositions including tocopherol and uses thereof
WO2011113000A8 (en) Novel ester containing compositions and methods